相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
Pegah Golabi et al.
ANNALS OF HEPATOLOGY (2022)
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani et al.
GUT (2022)
Bariatric Surgery in NAFLD
Mahak Chauhan et al.
DIGESTIVE DISEASES AND SCIENCES (2022)
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
Lingxuan An et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2022)
Baveno VII - Renewing consensus in portal hypertension
Roberto de Franchis et al.
JOURNAL OF HEPATOLOGY (2022)
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men
Jun Li et al.
GUT (2022)
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Ferenc Emil Mozes et al.
GUT (2022)
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Pere Gines et al.
HEPATOLOGY (2022)
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2022)
Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
Yamei Duan et al.
FRONTIERS IN IMMUNOLOGY (2022)
Global multi-stakeholder endorsement of the MAFLD definition
Nahum Mendez-Sanchez et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Michelle T. Long et al.
GASTROENTEROLOGY (2022)
Macronutrient and Micronutrient Intake in Adolescents With Non-alcoholic Fatty Liver Disease: The Association With Disease Severity
Ariel Porto et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)
Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials
Danielle Lee et al.
NUTRIENTS (2022)
GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond
Margit Mahlapuu et al.
HEPATOLOGY COMMUNICATIONS (2022)
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany
Yvonne Huber et al.
HEPATOLOGY COMMUNICATIONS (2022)
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH
Christian L. Horn et al.
HEPATOLOGY COMMUNICATIONS (2022)
Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability
Yen Chin Koay et al.
CARDIOVASCULAR RESEARCH (2021)
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Zobair M. Younossi et al.
HEPATOLOGY (2021)
Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults
Louise J. M. Alferink et al.
HEPATOLOGY (2021)
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon et al.
GUT (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Research in brief
Holly Baker
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Higher intake of whole grains and dietary fiber are associated with lower risk of liver cancer and chronic liver disease mortality
Xing Liu et al.
NATURE COMMUNICATIONS (2021)
Non-alcoholic fatty liver disease
Elizabeth E. Powell et al.
LANCET (2021)
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis
Yongtao Xiao et al.
LIVER INTERNATIONAL (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic aspects of bile acid signalling in the gut-liver axis
Benedikt Simbrunner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2021)
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update
Annalisa Berzigotti et al.
JOURNAL OF HEPATOLOGY (2021)
24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation
Ci Zhu et al.
JOURNAL OF HEPATOLOGY (2021)
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg et al.
NATURE METABOLISM (2021)
STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes
Mara Caputo et al.
HEPATOLOGY COMMUNICATIONS (2021)
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison et al.
HEPATOLOGY COMMUNICATIONS (2021)
Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis
Meghan Mooring et al.
HEPATOLOGY (2020)
Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis
Sejeong Kim et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2020)
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
A. Mantovani et al.
DIABETES & METABOLISM (2020)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease
Silvia Sookoian et al.
GUT (2020)
Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD
Guido Carpino et al.
HEPATOLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Mohammad Shadab Siddiqui et al.
JOURNAL OF HEPATOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics
Laurent Castera
LIVER INTERNATIONAL (2020)
The microbiome modulating activity of bile acids
Yuan Tian et al.
GUT MICROBES (2020)
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher et al.
GUT (2020)
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Michitaka Matsuda et al.
SEMINARS IN LIVER DISEASE (2020)
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Tiangang Li et al.
HEPATOBILIARY SURGERY AND NUTRITION (2020)
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron-Wisnewsky et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
From NAFLD to MAFLD: when pathophysiology succeeds
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Stefano Fiorucci et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2020)
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Sakura Yamamura et al.
LIVER INTERNATIONAL (2020)
Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis
Toon J. I. De Munck et al.
LIVER INTERNATIONAL (2020)
Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice
Sarah Alsamman et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD
Giljae Lee et al.
NATURE COMMUNICATIONS (2020)
Circulating microbiome in blood of different circulatory compartments
Robert Schierwagen et al.
GUT (2019)
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
Ralph A. DeFronzo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
Soumik BasuRay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans
Emmelie Cansby et al.
FASEB JOURNAL (2019)
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Clara Depommier et al.
NATURE MEDICINE (2019)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
Stefan Traussnigg et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction
Sifan Chen et al.
CELL METABOLISM (2019)
Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
Claudio Tana et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis
Alessandro Mantovani et al.
LIVER INTERNATIONAL (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis
George N. Ioannou et al.
HEPATOLOGY COMMUNICATIONS (2019)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Cynthia Lebeaupin et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
JOURNAL OF HEPATOLOGY (2018)
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Lesley Hoyles et al.
NATURE MEDICINE (2018)
The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD
Taylor K. Soderborg et al.
NATURE COMMUNICATIONS (2018)
Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease
Monika Rau et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
Juan P. Arab et al.
HEPATOLOGY (2017)
Gut Microbiota Profiling of Pediatric Nonalcoholic Fatty Liver Disease and Obese Patients Unveiled by an Integrated Meta-omics-Based Approach
Federica Del Chierico et al.
HEPATOLOGY (2017)
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
Hubert Plovier et al.
NATURE MEDICINE (2017)
NAFLD and diabetes mellitus
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
How to Approach a Patient With Nonalcoholic Fatty Liver Disease
Herbert Tilg
GASTROENTEROLOGY (2017)
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Oscar Chavez-Talavera et al.
GASTROENTEROLOGY (2017)
The PNPLA3 Variant Associated With Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation
Soumik BasuRay et al.
HEPATOLOGY (2017)
Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Guangqin Xiao et al.
HEPATOLOGY (2017)
Bi-directional analysis between fatty liver and cardiovascular disease risk factors
Jiantao Ma et al.
JOURNAL OF HEPATOLOGY (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
CELL METABOLISM (2017)
Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans
Manoj Amrutkar et al.
DIABETOLOGIA (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Weifei Zhu et al.
CELL (2016)
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Xiaobo Wang et al.
CELL METABOLISM (2016)
STK25 is a critical determinant in nonalcoholic steatohepatitis
Manoj Amrutkar et al.
FASEB JOURNAL (2016)
Changes in Blood Microbiota Profiles Associated With Liver Fibrosis in Obese Patients: A Pilot Analysis
Benjamin Lelouvier et al.
HEPATOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Giovanni Targher et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
The Role of Cholesterol in the Pathogenesis of NASH
George N. Ioannou
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Mark A. Herman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis
Ahad Wahid et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Associations of gut-floradependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults
Yu-ming Chen et al.
SCIENTIFIC REPORTS (2016)
Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH
Manoj Amrutkar et al.
FASEB JOURNAL (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
Paola Portillo-Sanchez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Short-chain fatty acids in control of body weight and insulin sensitivity
Emanuel E. Canfora et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice
Jing Liu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2014)
PNPLA3 mediates hepatocyte triacylglycerol remodeling
Hanna Ruhanen et al.
JOURNAL OF LIPID RESEARCH (2014)
Alterations of the human gut microbiome in liver cirrhosis
Nan Qin et al.
NATURE (2014)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease
Maitreyi Raman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH
Lixin Zhu et al.
HEPATOLOGY (2013)
Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk
W. H. Wilson Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study
L. Gerber et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease
Hae-Ki Min et al.
CELL METABOLISM (2012)
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
Rohit Loomba et al.
HEPATOLOGY (2012)
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Ekihiro Seki et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease
Kristin D. Kistler et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Crosstalk of reactive oxygen species and NF-kappa B signaling
Michael J. Morgan et al.
CELL RESEARCH (2011)
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
Michael R. Charlton et al.
GASTROENTEROLOGY (2011)
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
Christopher D. Williams et al.
GASTROENTEROLOGY (2011)
Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis
Yanfei Chen et al.
HEPATOLOGY (2011)
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Naoki Kumashiro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase
Yin Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies
Joe West et al.
GASTROENTEROLOGY (2010)
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression
Alexander R. Moschen et al.
GUT (2010)
The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis
Mustafa S. Ascha et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance
Giovanni Tarantino et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Histopathology of nonalcoholic fatty liver disease
Elizabeth M. Brunt et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression
Alexander R. Moschen et al.
JOURNAL OF HEPATOLOGY (2009)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Habitual physical activity is associated with intrahepatic fat content in humans
Gianluca Perseghin et al.
DIABETES CARE (2007)
Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis
Montserrat Mari et al.
CELL METABOLISM (2006)
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases
C Loguercio et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis
E Albano et al.
GUT (2005)
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
DS Cai et al.
NATURE MEDICINE (2005)
IKK-β links inflammation to obesity-induced insulin resistance
MC Arkan et al.
NATURE MEDICINE (2005)
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
LA Adams et al.
JOURNAL OF HEPATOLOGY (2005)
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
VT Samuel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The gut microbiota as an environmental factor that regulates fat storage
F Bäckhed et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids
AJ Brown et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease
ZP Li et al.
HEPATOLOGY (2003)
Sugar and cardiovascular disease - A statement for healthcare professionals from the committee on nutrition of the council on nutrition, physical activity, and metabolism of the American Heart Association
BV Howard et al.
CIRCULATION (2002)
Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice
T Uesugi et al.
HEPATOLOGY (2001)
Mechanisms of disease: Cytokines in alcoholic and nonalcoholic steatohepatitis.
H Tilg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans
M Roden et al.
DIABETES (2000)
分享论文
